All In Biotech

Drug Trial Radar · NCT00610363

Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares

A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study, Tolerability, and Efficacy of Rilonacept for the Prevention of Gout Flares During Initiation of Allopurinol Therapy

Last checked: Nov 20, 2026Latest source record: May 2, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

83

Actual

Start

Nov 2007

Primary completion

Oct 2008

Study completion Oct 2008

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Feb 7, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a clinical research study to determine the safety and effectiveness of an experimental drug called rilonacept in participants with gout who were beginning another additional treatment. Participants participated in this study for approximately 24 weeks. Rilonacept was being studied for use in preventing gout attacks in participants who had gout.

Conditions

  • Gout

Interventions

  • RilonaceptBiological

    Rilonacept 320 mg loading dose on Day 1 followed by Rilonacept 160 mg/2 mL injections qw for 17 weeks.

  • Placebo (for Rilonacept)Other

    Placebo loading dose on Day 1 followed by single placebo injections (2 mL) qw for 17 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Gout Flares Per Participant Assessed From Day 1 to Day 84 (Week 12)Time frame: Day 1 (Baseline) to Day 84 (Week 12)

Locations

34 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    San Diego, California

  • Site not named

    Santa Maria, California

  • Site not named

    Whittier, California

  • Site not named

    Colorado Srings, Colorado

  • Site not named

    DeLand, Florida

  • Site not named

    Ocala, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    St. Petersburg, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Dunwoody, Georgia

  • Site not named

    Honolulu, Hawaii

  • Site not named

    Boise, Idaho

  • Site not named

    Indianapolis, Indiana

  • Site not named

    South Bend, Indiana

  • Site not named

    Owensboro, Kentucky

  • Site not named

    Wheaton, Maryland

  • Site not named

    Billings, Montana

  • Site not named

    Omaha, Nebraska

  • Site not named

    Reno, Nevada

  • Site not named

    Albany, New York

  • Site not named

    Plainview, New York

  • Site not named

    Roslyn, New York

  • Site not named

    Monroe, North Carolina

  • Site not named

    Raleigh, North Carolina

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Mayfield Village, Ohio

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Duncansville, Pennsylvania

  • Site not named

    West Reading, Pennsylvania

  • Site not named

    Charleston, South Carolina

  • Site not named

    Grenville, South Carolina

  • Site not named

    Dallas, Texas

  • Site not named

    Spokane, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.